Trade Names:Dexedrine- Tablets 5 mg
Trade Names:Dexedrine Spansules- Capsules, sustained-release 5 mg- Capsules, sustained-release 10 mg- Capsules, sustained-release 15 mg
Trade Names:Dextrostat- Tablets 5 mg
Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.
Well absorbed. T max approximately 3 h (IR tablets) and approximately 8 h (SR capsules).
Widely distributed with high concentrations in the brain.
Metabolized in the liver by hydroxylation, N-deakylation and deamination.
t ½ approximately 12 h (urine pH less than 5.6, t ½ is 7 to 8 h; urine pH alkaline, t ½ is 18.6 to 33.6 h).
Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.
Advanced arteriosclerosis; symptomatic CV disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.
PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.Children (6 to 12 yr of age)
PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.Attention Deficit DisorderChildren 6 yr of age and older
PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose every morning.Children 3 to 5 yr of age
PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose every morning.Exogenous ObesityAdults 12 yr of age and older
PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. For long-acting form, 10 to 15 mg every morning.
Dispense in a tight, light-resistant container. Store at 15° to 30°C (59° to 86°F).
Amphetamines may decrease effectiveness.MAOIs, furazolidone
Hypertensive crisis and intracranial hemorrhage may occur.Tricyclic antidepressants
May decrease amphetamine effect.Urinary acidifiers (eg, ammonium chloride, ascorbic acid)
May decrease amphetamine levels.Urinary alkalinizers (eg, acetazolamide, sodium bicarbonate)
May increase amphetamine levels.
Plasma and urinary steroid levels may be altered.
Palpitations; tachycardia; hypertension; arrhythmias.
Nervousness; tremors; dizziness; insomnia, euphoria; headache.
Dry mouth; unpleasant taste.
Diarrhea; constipation; anorexia.
Drug dependence may develop with chronic use. Avoid prolonged periods of use.
High abuse/diversion potential.
Prescribe/dispense sparingly because of high diversion potential.
Category C .
Excreted in breast milk.
Do not use as anorectic agent in children younger than 12 yr of age. Not recommended for attention-deficit disorder in children younger than 3 yr of age.
Some products contain tartrazine, which may cause allergic reactions in susceptible individuals.
Tolerance may occur; do not exceed recommended dose to overcome this.
Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps.
Copyright © 2009 Wolters Kluwer Health.